SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): August 12, 2013

ADVANCED CELL TECHNOLOGY, INC.

(Exact name of registrant as specified in its charter)

33 Locke Drive, Marlborough, MA 01752

(Address of principal executive offices, including zip code)

(508) 756-1212

(Registrant’s telephone number, including area code)

_________________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

x Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CAR 240.13e-4(c))

Item 8.01 Other Events.

On August 12, 2013, Advanced Cell Technology, Inc. (the “Company”) issued a press release regarding the election of members to its board of directors, a proposed reverse stock split, a proposed increase in the number of authorized shares of its common stock, and other matters to be acted upon at the Company’s annual meeting of shareholders to be held on October 22, 2013. A copy of the Company’s press release is attached hereto as Exhibit 99.1.

Additional Information and Where to Find It

The Company will file with the Securities and Exchange Commission (the “SEC”) and will furnish to stockholders of record on the record date for the annual meeting a definitive proxy statement in connection with the election of members to its board of directors, reverse stock split, increase in authorized shares of common stock, and other matters to be acted upon at the annual meeting. The Company, its chief executive officer Gary Rabin, and certain of its directors, executive officers and other members of management may, under SEC rules, be deemed “participants” in the solicitation of proxies from the Company’s stockholders with respect to the election of members to its board of directors, reverse stock split, increase in authorized shares of common stock, and the other matters to be acted upon at the annual meeting. INVESTORS AND STOCKHOLDERS ARE ADVISED TO READ THE DEFINITIVE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED DIRECTOR NOMINEES, REVERSE STOCK SPLIT AND increase in authorized shares of common stock, AS WELL AS OTHER IMPORTANT INFORMATION INCLUDING THOSE PERSONS WHO MAY BE DEEMED “PARTICIPANTS” IN THE SOLICITATION. Investors and stockholders may obtain a free copy of the definitive proxy statement, and other documents filed by the Company with the SEC (including the preliminary proxy statement), at the SEC’s web site at http://www.sec.gov. Free copies of the definitive proxy statement and the Company’s other filings with the SEC may also be obtained from the Company by directing a request to Advanced Cell Technology, Inc., 33 Locke Drive, Marlborough, Massachusetts 01752, Attention: Secretary.

Item 9.01 Financial Statements and Exhibits.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 12, 2013

EXHIBIT INDEX